Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 48 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

8%

4 trials in Phase 3/4

Results Transparency

10%

1 of 10 completed trials have results

Key Signals

24 recruiting1 with results

Enrollment Performance

Analytics

N/A
10(38.5%)
Phase 2
8(30.8%)
Phase 3
3(11.5%)
Phase 1
2(7.7%)
Early Phase 1
2(7.7%)
Phase 4
1(3.8%)
26Total
N/A(10)
Phase 2(8)
Phase 3(3)
Phase 1(2)
+2 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (48)

Showing 20 of 48 trials
NCT07505173Phase 2Recruiting

Hippocampus-Protective Radiotherapy Combined With Osimertinib for Symptomatic Brain Metastases in EGFR-Mutated Lung Cancer

Role: collaborator

NCT03657732Recruiting

The Chinese Familial Alzheimer's Network

Role: collaborator

NCT06681948Not ApplicableCompleted

The Ketogenic Diet in the Treatment of Alzheimer's Disease

Role: collaborator

NCT03653156Recruiting

China Cognition and Aging Study

Role: collaborator

NCT07386015Recruiting

Etiology-Phenotype-Outcome Pathway Study on Freezing of Gait (FOG)

Role: lead

NCT06308952Phase 4Recruiting

Atorvastatin Pretreatment in Cerebrovascular Events (APICES) After Flow Diverter Implantation

Role: collaborator

NCT07392528Early Phase 1Not Yet Recruiting

Universal Chimeric Antigen Receptor T-Cell （UCAR T-cell） Therapy Targeting CD19/ BCMA（QT-019C） in Patients With r/ r Neurological Autoimmune Diseases

Role: lead

NCT07365475Phase 2Not Yet Recruiting

Efficacy and Safety of Intra-Arterial Albumin as Adjunct to Mechanical Thrombectomy in Acute Ischemic Stroke

Role: lead

NCT07294391Phase 2Not Yet Recruiting

The Preliminary Efficacy and Safety of Intra-Arterial Albumin as Adjunct to Mechanical Thrombectomy in Acute Ischemic Stroke

Role: lead

NCT06967025Phase 2Completed

Ischemic Postconditioning in Acute Stroke Patients Receiving Endovascular Thrombectomy

Role: lead

NCT06939166Early Phase 1Recruiting

Universal Chimeric Antigen Receptor T-Cell （UCAR T-cell） Therapy Targeting CD19/B Cell Maturation Antigen （CD19/BCMA） in Patients With r/r Neurological Autoimmune Diseases

Role: lead

NCT07115511Not ApplicableRecruiting

Combined Recanalization Therapy for Acute Large Vessel Occlusion Stroke

Role: lead

NCT05697588Recruiting

Exploring the Predicting Biomarkers From Mild Cognitive Impairment to Dementia (EBMID)

Role: collaborator

NCT05953623Phase 1Completed

Intra-arterial Albumin Infusion After Endovascular Therapy for Stroke Patients

Role: lead

NCT07031544Not ApplicableRecruiting

Efficacy and Influencing Factors of ALIC-NAc Deep Brain Stimulation in Treatment-Refractory Obsessive-Compulsive Disorder

Role: collaborator

NCT06949865Recruiting

AI-Enhanced Optimization of Acute Levodopa Challenge Test

Role: collaborator

NCT06510634Enrolling By Invitation

Triage of Patients Presenting Beyond 24 Hours With Ischemic Stroke Due to Vertebrobasilar Artery Occlusion

Role: lead

NCT06742450Not ApplicableRecruiting

Constant Current Versus Constant Voltage Subthalamic Nucleus Deep Brain Stimulation in Patients with Parkinson's Disease

Role: collaborator

NCT06419101Recruiting

Exploring the Diagnostic Biomarkers of Cognitive Disorders in China

Role: collaborator

NCT06621121Recruiting

A Real-world Study of Tenecteplase Versus Alteplase for Thrombolysis in Patients Within 4.5 H of Onset of Ischemic Stroke

Role: lead